Median OS was 4.6 months (95% CI, 4.0–5.1) and 6.9 months (4.2–9.7) for patients with a KRAS-mutated tumor (n = 83) and KRAS-wild-type tumor (n = 53), respectively (HR, 1.67, 95% CI, 1.08–2.59; p = 0.02). This evidence concerns the gene KRAS and neoplasm.